Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Revenue (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Revenue for 9 consecutive years, with $75.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 27.72% year-over-year to $75.5 million, compared with a TTM value of $228.4 million through Dec 2025, down 0.91%, and an annual FY2025 reading of $228.4 million, down 0.91% over the prior year.
  • Revenue was $75.5 million for Q4 2025 at Puma Biotechnology, up from $54.5 million in the prior quarter.
  • Across five years, Revenue topped out at $98.2 million in Q1 2021 and bottomed at $43.8 million in Q1 2024.
  • Average Revenue over 5 years is $59.9 million, with a median of $55.0 million recorded in 2021.
  • The sharpest move saw Revenue surged 91.67% in 2021, then crashed 53.41% in 2022.
  • Year by year, Revenue stood at $55.4 million in 2021, then skyrocketed by 58.33% to $87.6 million in 2022, then decreased by 17.65% to $72.2 million in 2023, then dropped by 18.15% to $59.1 million in 2024, then grew by 27.72% to $75.5 million in 2025.
  • Business Quant data shows Revenue for PBYI at $75.5 million in Q4 2025, $54.5 million in Q3 2025, and $52.4 million in Q2 2025.